Abstract
Adenocarcinomas and active granulomas often present similarly on computed tomography (CT) and positron emission tomography (PET) scans, frequently leading to unnecessary invasive biopsies for benign cases. This study introduces quantitative vessel tortuosity (QVT), a novel CT imaging biomarker, to differentiate these conditions. Using a cohort of 290 patients across two institutions, a machine learning classifier based on QVT features achieved an area under the receiver operating characteristic curve (AUC) of 0.85 in independent validation. This significantly outperformed human experts (AUC ~0.61), traditional radiomic features (AUC 0.73), and deep learning models (AUC 0.76), suggesting QVT's potential as a non-invasive diagnostic tool.
Introduction
Distinguishing between malignant lung adenocarcinomas and benign inflammatory granulomas is a significant clinical challenge. Both can appear "spiculated" on standard CT scans and show high metabolic activity on PET scans. Due to these similarities, approximately 30% of patients with benign nodules undergo invasive surgical procedures to rule out cancer, incurring high costs and risks. This research explores the surrounding vasculature's architecture—specifically its "twistedness"—as a discriminative "radiomic" signature.
Methods
The study developed a comprehensive pipeline to quantify the tortuosity of vessels associated with lung nodules.
The process involves four primary stages:
- Segmentation: Radiologists identify a 3D volume of interest, and a 3D region-growing algorithm isolates the nodule and its associated vasculature.
- Skeletonization: Centerlines of the segmented vessels are extracted using a "fast marching" algorithm.
- Feature Extraction: 35 QVT features are calculated based on tortuosity (vessel length vs. straight-line distance), curvature (bending degree), and branching complexity.
- Machine Learning: A Support Vector Machine (SVM) classifier is trained using the most stable and informative features selected via minimum Redundancy Maximum Relevance (mRMR).
Datasets
The primary cohort included 290 patients, split into a Training Set (N=145) and an Independent Validation Set (N=145). Additionally, the public RIDER dataset (N=31) was used to assess feature stability across test-retest scans.
Results
The QVT-based classifier demonstrated superior diagnostic performance compared to traditional methods and human interpretation.
Key findings include:
- High Accuracy: The QVT model achieved an AUC of 0.85 on the independent validation set.
- Human vs. Machine: Human experts (a radiologist and a pulmonologist) achieved AUCs of only 0.61 and 0.60, respectively, on the same data.
- Comparison with AI Models: QVT outperformed standard radiomics (AUC 0.73) and deep learning architectures like LeNet (AUC 0.76) and VGG-19.
- Robustness: Feature stability analysis using the RIDER dataset identified a subset of QVT features, such as maximum curvature, that remain highly reproducible across different scan conditions.
Discussion
The success of QVT is rooted in the biology of angiogenesis. Malignant tumors rapidly recruit new blood vessels, which grow haphazardly and result in more tortuous shapes than those found near benign granulomas. While most radiomic studies focus on the nodule's internal texture, these results suggest that the surrounding environment provides more discriminative information.
The poor performance of human experts highlights that vessel tortuosity is a "sub-visual" feature—quantifiable by AI but difficult for the human eye to assess accurately. However, the method's reliance on high-quality 3D vessel segmentation remains a limitation, as errors in isolating small vessels can lead to unstable feature values. Future work should expand the scope to other benign mimics and validate these findings in prospective clinical trials.
Conclusion
Quantitative vessel tortuosity represents a promising, non-invasive imaging biomarker. By accurately distinguishing adenocarcinomas from granulomas on routine non-contrast CT scans, QVT could significantly reduce unnecessary invasive procedures and improve patient management in lung cancer screening.
Summary updated